Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data

BACKGROUND: Patients with chronic kidney disease (CKD) are at risk of progression to end-stage renal disease and cardiovascular disease. Data from other populations and animal experiments suggest that neprilysin inhibition (which augments the natriuretic peptide system) may reduce these risks, but c...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837485/
https://www.ncbi.nlm.nih.gov/pubmed/27646835
http://dx.doi.org/10.1093/ndt/gfw321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837485/
https://www.ncbi.nlm.nih.gov/pubmed/27646835
http://dx.doi.org/10.1093/ndt/gfw321

Ejemplares similares